Amgen Seeking ESA Dosing Algorithm As Scripts Continue To Fall In Oncology
Executive Summary
Amgen is taking steps to construct dosing algorithms for its erythropoiesis-stimulating agents that may help mitigate problems stemming from heterogeneous patient response to the anemia therapies
You may also be interested in...
Amgen, J&J Propose New Target Range For Aranesp, Procrit
Just a year after FDA removed information related to a dosing target range for erythropoiesis-stimulating agents from product labeling, Amgen and Johnson & Johnson are proposing to re-establish a specific hemoglobin target range for the anemia therapies
Amgen, J&J Propose New Target Range For Aranesp, Procrit
Just a year after FDA removed information related to a dosing target range for erythropoiesis-stimulating agents from product labeling, Amgen and Johnson & Johnson are proposing to re-establish a specific hemoglobin target range for the anemia therapies
ESA Labeling Should Explain Hemoglobin Target, Advisory Committee Says
Treatment targets for erythropoiesis-stimulating agents in the renal setting need to be accompanied by clinical management information, FDA's Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees says